Sign up to save your podcasts
Or
Share EP16 - The Co-Investor Question That Determines Everything in Biotech and Medtech
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
EP16 - The Co-Investor Question That Determines Everything in Biotech and Medtech
This is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact.
In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech.
If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a governance system. The wrong co-investors can slow execution, distort milestones, and burn capital. The right co-investors create speed, trust, and real de-risk.
What we cover:
Why investor labels matter less than incentives and behavior
Skin in the game, and why it changes decision quality
Two co-investor archetypes that create real synergy
How family offices think, and why relationships and values come first
Europe versus Asia: differences in investor mindset and culture
Why smaller, domain-specific funds are gaining momentum
Practical questions founders and investors should ask before partnering
Who this is for: Founders in biotech and medtech, healthcare VCs, family offices, corporate venture teams, private equity, and operators building clinical infrastructure.
Timecode:
00:00 Introduction to Key Stakeholders
00:22 Types of Co-Investors
01:09 Value Proposition and Commitment
02:10 Investor Specialization and Synergies
03:26 Role of Angel Investors
04:02 Corporate Venture Capital
04:44 Family Offices and Personal Touch
08:56 Challenges in Different Regions
09:32 Building Relationships with Investors
10:34 High Net Worth Individuals
18:02 Micro Funds and Emerging Managers
19:51 Conclusion and Future Outlook
Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.
Links:
Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/
Peter M. Kovacs Personal Website:https://www.petermkovacs.com/
PMK Group Website: https://www.pmk-group.com/
Guests:
Károly Szántó: https://www.linkedin.com/in/karolyszanto1/
Thijmen Meijer: https://www.linkedin.com/in/thmnmr/
UniPrisma: https://uniprisma.com/
View all episodes
By Dr. Peter M. KovacsThis is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact.
In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech.
If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a governance system. The wrong co-investors can slow execution, distort milestones, and burn capital. The right co-investors create speed, trust, and real de-risk.
What we cover:
Why investor labels matter less than incentives and behavior
Skin in the game, and why it changes decision quality
Two co-investor archetypes that create real synergy
How family offices think, and why relationships and values come first
Europe versus Asia: differences in investor mindset and culture
Why smaller, domain-specific funds are gaining momentum
Practical questions founders and investors should ask before partnering
Who this is for: Founders in biotech and medtech, healthcare VCs, family offices, corporate venture teams, private equity, and operators building clinical infrastructure.
Timecode:
00:00 Introduction to Key Stakeholders
00:22 Types of Co-Investors
01:09 Value Proposition and Commitment
02:10 Investor Specialization and Synergies
03:26 Role of Angel Investors
04:02 Corporate Venture Capital
04:44 Family Offices and Personal Touch
08:56 Challenges in Different Regions
09:32 Building Relationships with Investors
10:34 High Net Worth Individuals
18:02 Micro Funds and Emerging Managers
19:51 Conclusion and Future Outlook
Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.
Links:
Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/
Peter M. Kovacs Personal Website:https://www.petermkovacs.com/
PMK Group Website: https://www.pmk-group.com/
Guests:
Károly Szántó: https://www.linkedin.com/in/karolyszanto1/
Thijmen Meijer: https://www.linkedin.com/in/thmnmr/
UniPrisma: https://uniprisma.com/